Amylyx Pharmaceuticals
AMLX
154 hedge funds and large institutions have $1.18B invested in Amylyx Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 66 increasing their positions, 43 reducing their positions, and 21 closing their positions.
53% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 43
38% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 21
26% more call options, than puts
Call options by funds: $46.9M | Put options by funds: $37.2M
5% more funds holding
Funds holding: 147 → 154 (+7)
4.19% more ownership
Funds ownership: 77% → 81.19% (+4.2%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
22% less capital invested
Capital invested by funds: $1.51B → $1.18B (-$331M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$30.3M |
| 2 |
Millennium Management
New York
|
+$22.9M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$22.7M |
| 4 |
Balyasny Asset Management
Chicago,
Illinois
|
+$20.3M |
| 5 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$17.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$31.3M |
| 2 |
DM
Deerfield Management
New York
|
-$25.2M |
| 3 |
O
OrbiMed
New York
|
-$23.9M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
-$22.5M |
| 5 |
ACA
Avoro Capital Advisors
New York
|
-$13.9M |
AMLX Hedge Fund Activity: Q2 2023 in Review
154 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Amylyx Pharmaceuticals (AMLX) for Q2 2023, worth a combined $1.18B — down 22% from $1.51B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AMLX positions and 21 closed out — a net gain of 8 holders — while 66 added to existing stakes and 43 trimmed.
The largest buyer was Stonepine Capital Management, opening a new position worth an estimated $30.3M. The largest seller was Perceptive Advisors, cutting an estimated $31.3M.
- 154 institutional investors held Amylyx Pharmaceuticals (AMLX) as of Q2 2023, up from 147 in Q1 2023.
- Funds reported $1.18B of Amylyx Pharmaceuticals stock for Q2 2023, down 22% quarter-over-quarter.
- 29 funds opened new Amylyx Pharmaceuticals positions in Q2 2023 and 21 closed out, a net change of +8 holders.
- The largest Amylyx Pharmaceuticals buyer in Q2 2023 was Stonepine Capital Management, an estimated $30.3M added.
- The largest Amylyx Pharmaceuticals seller in Q2 2023 was Perceptive Advisors, an estimated $31.3M sold.
Based on aggregated 13F filings for Q2 2023.